Summary & Overview
HCPCS J7325: Hyaluronan (Synvisc) for Intra-articular Injection, 1 mg
HCPCS Level II code J7325 designates hyaluronan or derivative (Synvisc or Synvisc-One) supplied for intra-articular injection, billed per 1 mg. This code is used nationally to report viscosupplementation products administered directly into joint spaces — commonly for symptomatic relief in degenerative joint conditions. Accurate coding of J7325 affects drug billing, payer coverage determinations, and site-of-service reporting for outpatient musculoskeletal care.
Key payers considered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how J7325 is defined clinically, where the service is typically provided, and what documentation elements are relevant for claims submission. The publication summarizes common payer coverage patterns, allowable reporting practices, and benchmark considerations for unit-based drug billing.
The report provides practical benchmarking context, highlights recent policy clarifications that affect injectable hyaluronan billing, and outlines clinical context for use of Synvisc products. It is intended for billing managers, revenue cycle professionals, and clinicians seeking a national-level reference on classification, typical sites of service, and payer landscape for J7325. Data not available in the input will be noted explicitly in the detailed sections.
Billing Code Overview
HCPCS Level II code J7325 represents hyaluronan or derivative (Synvisc or Synvisc-One) supplied for intra-articular injection, reported per 1 mg. This drug code covers viscosupplementation products used for injection into a joint space to provide lubrication and cushioning.
Service type: Intra-articular injectable medication
Typical site of service: Outpatient clinic or physician office, ambulatory surgical center, or other outpatient settings where joint injections are performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with symptomatic knee osteoarthritis presents to an orthopedic clinic for targeted intra-articular viscosupplementation. The patient has chronic knee pain, stiffness worse with weight-bearing, intermittent swelling, and limited range of motion despite NSAIDs, physical therapy, and activity modification. After clinical evaluation and review of contraindications, the clinician prepares J7325 (hyaluronan, Synvisc or Synvisc-One, for intra-articular injection, 1 mg) for administration into the affected knee joint. The typical workflow includes verification of patient identity and informed consent, review of anticoagulation status and allergies, procedural timeout, aseptic skin preparation, local anesthesia as needed, ultrasound or landmark-guided intra-articular injection, post-procedure observation for immediate reactions, documentation of lot number and units of J7325 administered, and scheduling of follow-up for pain and function assessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct procedural service | Use when reporting a separate, unrelated service or procedure performed on the same day as another service to indicate it was distinct and not bundled. |